Effect of age on efficacy and safety of vorapaxar in patients with non –ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial
Conclusion Older patients had a greater risk for ischemic and bleeding events; however, the efficacy and safety of vorapaxar in NSTE ACS were not significantly influenced by age.
Source: American Heart Journal - Category: Cardiology Source Type: research
More News: Bleeding | Cardiology | Cardiovascular | Heart | Heart Attack | Hypertension | Ischemic Stroke | Stroke